Transglutaminase 2 serves as a pathogenic hub gene of KRAS mutant colon cancer based on integrated analysis

Table 2 Chi-square tests between transglutaminase 2 level and clinicopathological characteristic in entire patient cohort, n (%)

Clinical parameters	TGM2 expression level		χ2	P value
	Low (n = 44)	High (n = 46)
Age			0.148	0.701
≤ 60	18 (40.91)	17 (36.96)
> 60	26 (59.09)	29 (63.04)
Gender			0.046	0.829
Female	23 (52.27)	23 (50.00)
Male	21 (47.73)	23 (50.00)
Histologic grade			0.667	0.414
Grade II	26 (59.09)	31 (67.39)
Grade III	18 (40.91)	15 (32.61)
Tumor size			0.525	0.469
< 5 cm	14 (31.82)	18 (39.13)
≥ 5 cm	30 (68.18)	28 (60.87)
Lympho-vascular invasion			6.183	0.013a
No	34 (77.27)	24 (52.17)
Yes	10 (22.73)	22 (47.83)
Perineural invasion			2.423	0.120
No	39 (88.64)	35 (76.09)
Yes	5 (11.36)	11 (23.91)
Pathologic T stage			1.076	0.300
T2-T3	22 (50.00)	18 (39.13)
T4a-T4b	22 (50.00)	28 (60.87)
Pathologic N stage			0.073	0.787
N0	28 (63.64)	28 (60.87)
N1-2	16 (36.36)	18 (39.13)
Clinical M stage			0.000	1.000
M0	42 (95.45)	44 (95.65)
M1	2 (4.55)	2 (4.35)
Disease stage			0.067	0.796
Stage I & II	27 (61.36)	27 (58.70)
Stage III & IV	17 (38.64)	19 (41.30)
CD8 positive rate			0.022	0.881
< 5%	29 (65.91)	31 (67.39)
≥ 5%	15 (34.09)	15 (32.61)
PD-L1 positive rate			0.686	0.408
< 5%	29 (65.91)	34 (73.91)
≥ 5%	15 (34.09)	12 (26.09)
PD-1 positive rate			1.699	0.192
< 5%	35 (79.55)	31 (67.39)
≥ 5%	9 (20.45)	15 (32.61)
KRAS mutant status			0.098	0.754
Wild type	31 (70.45)	31 (67.39)
Mutation	13 (29.55)	15 (32.61)

^aP < 0.05.

TGM2: Transglutaminase 2; PD-L1: Programmed death ligand 1; PD1: Programmed cell death 1.